SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-24-011948
Filing Date
2024-04-15
Accepted
2024-04-15 07:45:55
Documents
14
Period of Report
2024-04-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 4.02: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

Document Format Files

Seq Description Document Type Size
1 FORM 8-K rvph20240411_8k.htm   iXBRL 8-K 41146
  Complete submission text file 0001437749-24-011948.txt   194212

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA rvph-20240412.xsd EX-101.SCH 3914
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rvph-20240412_def.xml EX-101.DEF 13477
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvph-20240412_lab.xml EX-101.LAB 17737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvph-20240412_pre.xml EX-101.PRE 13454
17 EXTRACTED XBRL INSTANCE DOCUMENT rvph20240411_8k_htm.xml XML 4876
Mailing Address 10080 N WOLFE ROAD SUITE SW3-200 CUPERTINO CA 95014
Business Address 10080 N WOLFE ROAD SUITE SW3-200 CUPERTINO CA 95014 4085018881
REVIVA PHARMACEUTICALS HOLDINGS, INC. (Filer) CIK: 0001742927 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38634 | Film No.: 24843126
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)